M

Maccura Biotechnology Co Ltd
SZSE:300463

Watchlist Manager
Maccura Biotechnology Co Ltd
SZSE:300463
Watchlist
Price: 10.49 CNY -0.94% Market Closed
Market Cap: ¥6.3B

EV/S

2.9
Current
1%
More Expensive
vs 3-y average of 2.9

Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.

EV/S
2.9
=
Enterprise Value
¥6.5B
/
Revenue
¥2.2B

Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.

EV/S
2.9
=
Enterprise Value
¥6.5B
/
Revenue
¥2.2B

Valuation Scenarios

Maccura Biotechnology Co Ltd is trading above its 3-year average

If EV/S returns to its 3-Year Average (2.9), the stock would be worth ¥10.41 (1% downside from current price).

Statistics
Positive Scenarios
3/4
Maximum Downside
-1%
Maximum Upside
+110%
Average Upside
31%
Scenario EV/S Value Implied Price Upside/Downside
Current Multiple 2.9 ¥10.49
0%
3-Year Average 2.9 ¥10.41
-1%
5-Year Average 3 ¥10.69
+2%
Industry Average 6.1 ¥22.02
+110%
Country Average 3.3 ¥11.82
+13%

Forward EV/S
Today’s price vs future revenue

Today's Enterprise Value Revenue Forward EV/S
¥6.5B
/
Oct 2025
¥2.2B
=
2.9
Current
¥6.5B
/
Dec 2025
¥2.4B
=
2.8
Forward
¥6.5B
/
Dec 2026
¥2.5B
=
2.7
Forward
¥6.5B
/
Dec 2027
¥2.6B
=
2.5
Forward

Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.

Peer Comparison

All Multiples
EV/S
P/E
All Countries
Close
Market Cap EV/S P/E
CN
Maccura Biotechnology Co Ltd
SZSE:300463
6.3B CNY 2.9 -54
US
PerkinElmer Inc
LSE:0KHE
936.1B USD 328.4 3 881
US
Thermo Fisher Scientific Inc
NYSE:TMO
174.4B USD 4.7 25.5
US
Danaher Corp
NYSE:DHR
124B USD 5.5 33.6
KR
Samsung Biologics Co Ltd
KRX:207940
82.3T KRW 17.9 46.1
CN
WuXi AppTec Co Ltd
SSE:603259
326.9B CNY 6.4 17.1
CH
Lonza Group AG
SIX:LONN
32.9B CHF 5.5 -119.6
US
Agilent Technologies Inc
NYSE:A
32.4B USD 4.8 25.1
US
Waters Corp
NYSE:WAT
30.1B USD 9.6 46.9
US
IQVIA Holdings Inc
NYSE:IQV
26.8B USD 2.4 19.8
US
Mettler-Toledo International Inc
NYSE:MTD
25.8B USD 6.9 29.7
P/E Multiple
Earnings Growth PEG
CN
M
Maccura Biotechnology Co Ltd
SZSE:300463
Average P/E: 458.3
Negative Multiple: -54
37%
N/A
US
P
PerkinElmer Inc
LSE:0KHE
3 881
46%
84.4
US
Thermo Fisher Scientific Inc
NYSE:TMO
25.5
18%
1.4
US
Danaher Corp
NYSE:DHR
33.6
26%
1.3
KR
Samsung Biologics Co Ltd
KRX:207940
46.1
15%
3.1
CN
WuXi AppTec Co Ltd
SSE:603259
17.1
6%
2.8
CH
Lonza Group AG
SIX:LONN
Negative Multiple: -119.6 N/A N/A
US
Agilent Technologies Inc
NYSE:A
25.1
18%
1.4
US
Waters Corp
NYSE:WAT
46.9
41%
1.1
US
IQVIA Holdings Inc
NYSE:IQV
19.8
25%
0.8
US
Mettler-Toledo International Inc
NYSE:MTD
29.7
10%
3

Market Distribution

In line with most companies in China
Percentile
46th
Based on 7 593 companies
46th percentile
2.9
Low
0 — 1.7
Typical Range
1.7 — 6.2
High
6.2 —
Distribution Statistics
China
Min 0
30th Percentile 1.7
Median 3.3
70th Percentile 6.2
Max 5 034 353.9

Maccura Biotechnology Co Ltd
Glance View

Maccura Biotechnology Co. Ltd., rooted in Chengdu, China, has grown from a nascent enterprise into a significant player in the global in vitro diagnostics (IVD) industry. The company was established with a clear vision: to innovate and provide reliable diagnostic solutions. Over the years, Maccura has carved a niche by focusing on the development, manufacturing, and distribution of a comprehensive range of diagnostic products, including reagents, analyzers, and control materials. These products are crucial for diagnosing various conditions, from infectious diseases to chronic illnesses, allowing healthcare professionals to make informed decisions. Maccura's reputation is built on its commitment to rigorous research and development, ensuring its offerings meet an international standard of quality. The financial blueprint of Maccura lies predominantly in its ability to develop proprietary technology and leverage strategic partnerships across the globe. They generate revenue through the sale of diagnostic instruments and consumables, which are essential components that need frequent replenishing by hospitals and laboratories, creating a steady stream of income. Furthermore, Maccura continually invests in expanding its product lineup and enhancing production capabilities. By tapping into the rising demand for accurate and efficient diagnostic solutions, especially in the wake of global health challenges, Maccura has effectively positioned itself to capture a substantial market share both domestically and internationally. Through a well-orchestrated blend of innovation, quality assurance, and strategic growth initiatives, the company continues to solidify its status as a cornerstone in the healthcare diagnostics realm.

Intrinsic Value
8.18 CNY
Overvaluation 22%
Intrinsic Value
Price ¥10.49
M
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett